A Day Up For LRMR
LRMR (LRMR:NASDAQ) jumped higher at $18.91, a gain of 24.7%. The stock got featured on our News Catalysts scanner on Tue 13 Oct 20 at 10:17 AM in the 'MISCELLANEOUS' category. From Mon 28 Sep 20, the stock recorded 50.00% Up Days and 45.45% Green Days
The share price of the company has been moving sideways in recent weeks.
About LRMR (LRMR:NASDAQ)
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Top 10 Gainers:
- Medigus Ltd. (MDGS:NASDAQ), 52.91%
- PEDEVCO Corp. (PED:NYSEMKT), 34.33%
- Blonder Tongue Laboratories, Inc. (BDR:NYSEMKT), 34.04%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 33.11%
- J.Jill, Inc. (JILL:NYSE), 29.93%
- SOS (SOS:NYSE), 27.49%
- LRMR (LRMR:NASDAQ), 24.65%
- Onconova Therapeutics, Inc. (ONTX:NASDAQ), 24.46%
- Enlivex Therapeutics Ltd. (ENLV:NASDAQ), 22.74%
- Auris Medical Holding Ltd. (EARS:NASDAQ), 21.97%